NCT04169022View on ClinicalTrials.gov

AML Cell Immunotherapy Using Chimeric Antigen Receptor T-cells

NACompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

July 10, 2019

Primary Completion Date

October 2, 2023

Study Completion Date

October 2, 2023

Conditions
Acute Myeloid Leukemia
Interventions
OTHER

Sample collection

Sample collection blood and/or bone marrow

Trial Locations (1)

25000

CHU Besançon, Besançon

All Listed Sponsors
collaborator

Centre Hospitalier Universitaire Dijon

OTHER

collaborator

Etablissement Français du Sang

OTHER

lead

Centre Hospitalier Universitaire de Besancon

OTHER

NCT04169022 - AML Cell Immunotherapy Using Chimeric Antigen Receptor T-cells | Biotech Hunter | Biotech Hunter